Sana Biotech reported Q4 2025 net loss of USD 58.8 million (USD 0.21 per share) and FY 2025 net loss of USD 244.2 million (USD 0.96 per share). Q4 2025 R&D expenses were USD 34.9 million (down 22.6%) and G&A expenses were USD 12.2 million (down 29.5%). FY 2025 R&D expenses were USD 132.0 million (down 38.8%) and G&A expenses were USD 44.3 million (down 30.8%). Cash, cash equivalents and marketable securities totaled USD 138.4 million at Dec. 31, 2025, with expected cash runway into late 2026; non-GAAP operating cash burn for FY 2025 was USD 138.5 million. On the business side, Sana Biotech highlighted 12-month clinical results from the ongoing investigator-sponsored UP421 type 1 diabetes study showing hypoimmune-modified pancreatic islet cells transplanted without immunosuppression were safe and well-tolerated, evaded immune detection, and continued to function one year post-transplant, supported by circulating C-peptide and PET-MRI findings at weeks 12 and 52. The New England Journal of Medicine published positive 12-week UP421 results. The company said it is developing SC451, an O-negative, hypoimmune-modified, iPSC-derived pancreatic islet cell therapy, and expects to file an IND and begin a Phase 1 trial as early as this year. Sana Biotech also expects to generate first-in-human data as early as this year for SG293, its next-generation in vivo CAR T candidate, and reported non-human primate data with a surrogate showing deep B-cell depletion and immune reset without lymphodepleting chemotherapy. The company also reported raising aggregate gross proceeds of USD 133.7 million in 2025 from its ATM and an equity financing, and appointed Brian Piper as CFO in Q1 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603031605PRIMZONEFULLFEED9665052) on March 03, 2026, and is solely responsible for the information contained therein.
Comments